Collegium (ancient Rome)

Collegium Announces $25 Million Accelerated Share Repurchase Program

Retrieved on: 
Thursday, November 9, 2023
ASR, Jefferies Group, Share repurchase, Pharmaceutical industry, Collegium (ancient Rome)

Collegium will execute the ASR as part of the $100 million share repurchase program authorized by its Board of Directors in January 2023.

Key Points: 
  • Collegium will execute the ASR as part of the $100 million share repurchase program authorized by its Board of Directors in January 2023.
  • Upon completion of this ASR, Collegium will have $25 million remaining under the program.
  • “We are committed to opportunistically returning value to our shareholders through our share repurchase program.
  • As of September 30, 2023, Collegium had approximately 33.1 million shares outstanding.

Collegium Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Adjustment, Food, Medicare, EBITDA, Conference, Medicare Part D, Prescription, Tapentadol, Food and Drug Administration, Pharmaceutical industry, Bookkeeping, Management, Video game, Collegium (ancient Rome)

ET –

Key Points: 
  • ET –
    STOUGHTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter ended September 30, 2023, and provided a corporate update.
  • We are focused on creating value for our shareholders through the disciplined deployment of capital.”
    “We delivered a solid financial performance in the third quarter and are tightening our 2023 financial guidance ranges,” said Colleen Tupper, Chief Financial Officer of Collegium.
  • The financial strength of the business enables us to execute our capital deployment strategy in a disciplined manner, inclusive of our newly announced $25.0 million Accelerated Share Repurchase program.”
    Grew portfolio net revenue to $136.7 million in the quarter ended September 30, 2023 (the “2023 Quarter”), up 8% compared to the quarter ended September 30, 2022 (the “2022 Quarter”).
  • Generated record quarterly Belbuca net revenue of $45.4 million in the 2023 Quarter, up 17% year-over-year.

Collegium Announces $50 Million Accelerated Share Repurchase Program

Retrieved on: 
Monday, August 7, 2023
Jefferies Group, ASR, Share repurchase, Pharmaceutical industry, Collegium (ancient Rome)

STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock.

Key Points: 
  • STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock.
  • Collegium will execute the ASR as part of the $100 million share repurchase program authorized by its Board of Directors in January 2023.
  • Upon completion of this ASR, Collegium will have $50 million remaining under the program.
  • “The accelerated share repurchase program reinforces our confidence in Collegium's core business, financial strength and strategy,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium.

Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year

Retrieved on: 
Thursday, August 3, 2023
Growth, Adjustment, Conference, Pharmaceutical industry, Bookkeeping, Collegium (ancient Rome)

– Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year –

Key Points: 
  • – Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year –
    – Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year –
    – Conference Call Scheduled for Today at 4:30 p.m.
  • “We are on track to make 2023 a banner year.
  • Increased Xtampza® ER revenue 24% year-over-year to $41.2 million.
  • The Company reaffirms its full-year 2023 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA:

Collegium Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 4, 2023
Share repurchase, AAPM, American Academy, EBITDA, Annual general meeting, Adjustment, Conference, Management, Life insurance, Collegium (ancient Rome)

ET –

Key Points: 
  • ET –
    STOUGHTON, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter ended March 31, 2023, and provided a corporate update.
  • "We delivered record revenue and adjusted EBITDA in the first quarter driven by lower Xtampza ER gross-to-net, record Belbuca revenues and leveraging our fully synergized cost structure,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium.
  • We are on track to achieve our strategic and financial objectives, and we are confident that 2023 will be a banner year.”
    “Our strong performance in the first quarter demonstrates our financial strength and discipline,” said Colleen Tupper, Chief Financial Officer of Collegium.
  • The Company reaffirms its full-year 2023 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA:

Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
EBITDA, Alvogen, District court, ESG, Share repurchase, Federal, Acceleration, Judgement, Conference, City, Douglas v. U.S. District Court ex rel Talk America, Adjustment, Pharmaceutical industry, Life insurance, Collegium (ancient Rome)

STOUGHTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • ET –
    STOUGHTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.
  • “2022 was a pivotal year for Collegium Pharmaceutical.
  • We are committed to executing on our strategic priorities, including deploying capital in a disciplined manner, to create long-term value for shareholders.”
    “Our fourth quarter results demonstrate Collegium’s financial strength as we delivered record net revenue, record adjusted EBITDA and robust operating cash flows,” said Colleen Tupper, Chief Financial Officer of Collegium.
  • The Company reaffirms its full-year 2023 financial guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA:

Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report

Retrieved on: 
Wednesday, February 22, 2023
Benchmark, Science, technology, engineering, and mathematics, Electronic waste, Social, Corporate social responsibility, Culture, Corporation, ESG, Organization, Health, Biophysical environment, Growth, Social Security Government Pension Offset, Education, Organic, DEI, Environmental stewardship, STEM, Equity, Management, Collegium (ancient Rome), Mathematics, Engineering, Science

STOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its inaugural Environmental, Social and Governance (ESG) report.

Key Points: 
  • STOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its inaugural Environmental, Social and Governance (ESG) report.
  • In 2022, 92% of employees completed the corporate survey, and responses exceeded the Pharma Benchmark in nearly all areas.
  • Corporate Social Responsibility: Collegium directly supports organizations focused on expanding equitable access to Science, Technology, Engineering and Mathematics (STEM) education within the greater Boston area and nationwide.
  • In 2022, the Company donated over $350,000 in support of STEM charitable initiatives and other charities serving community members in need.

Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering

Retrieved on: 
Wednesday, February 8, 2023
Debt-to-GDP ratio, Sale, Acquisition, SEC Rule 144A, Note, Public expenditure, Exercise, Person, Security (finance), Collegium (ancient Rome)

The offering was upsized from the previously announced offering size of $175,000,000 aggregate principal amount of notes.

Key Points: 
  • The offering was upsized from the previously announced offering size of $175,000,000 aggregate principal amount of notes.
  • The sale of the notes to the initial purchasers is expected to settle on February 10, 2023, subject to customary closing conditions.
  • Before November 15, 2028, noteholders will have the right to convert their notes only upon the occurrence of certain events.
  • Contemporaneously with the pricing of the notes in the offering, Collegium entered into separate privately negotiated transactions with certain holders of the 2026 notes to repurchase $117.4 million aggregate principal amount of the 2026 notes for an aggregate of approximately $140.1 million of cash (collectively, the “2026 notes repurchases”), which includes accrued and unpaid interest on the 2026 notes to be repurchased.

Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering

Retrieved on: 
Monday, February 6, 2023
Debt-to-GDP ratio, Sale, Acquisition, SEC Rule 144A, Note, Public expenditure, Person, Security (finance), Car rental, Collegium (ancient Rome)

The notes will be senior, unsecured obligations of Collegium, will accrue interest payable semi-annually in arrears and will mature on February 15, 2029, unless earlier repurchased, redeemed or converted.

Key Points: 
  • The notes will be senior, unsecured obligations of Collegium, will accrue interest payable semi-annually in arrears and will mature on February 15, 2029, unless earlier repurchased, redeemed or converted.
  • The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.
  • Contemporaneously with the pricing of the notes in the offering, Collegium intends to enter into separate privately negotiated transactions with certain holders of the 2026 notes to repurchase a portion of such notes on terms to be negotiated with such holders (each a “note repurchase” and collectively the “2026 notes repurchases”).
  • Collegium expects that certain holders of 2026 notes that sell their 2026 notes in negotiated transactions with Collegium may enter into or unwind various derivatives with respect to Collegium’s common stock and/or purchase shares of its common stock in the market.

Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results

Retrieved on: 
Monday, February 6, 2023
Depreciation, Cyprus Securities and Exchange Commission, Conversation, GAAP, Tax, Result, Security (finance), Analysis, Acquisition, Compte rendu, Financial condition report, Sale, EBITDA, Public expenditure, Adjustment, Risk, Annual report, Pharmaceutical industry, Video game, Fossil fuel, Bookkeeping, Audit, Real estate, Insurance, Collegium (ancient Rome)

STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • -Final fourth quarter and full year 2022 financial results to be announced after market closes on Thursday, February 23-
    STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2022.
  • The preliminary, unaudited financial results included in this press release are based on information available as of February 6, 2023 and management's initial review of operations for the fourth quarter and year ended December 31, 2022.
  • They remain subject to change based on management's ongoing review of the fourth-quarter and full year results and are forward-looking statements.
  • We report these non-GAAP financial measures to portray the results of our operations prior to considering certain income statement elements.